Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in Non-Small Cell Lung Cancer

3

4 Karlijn Hummelink^{1,2}, Vincent van der Noort³, Mirte Muller², Robert D. Schouten², Michel

5 M. van den Heuvel^{2,4}, Daniela S. Thommen⁵, Egbert F. Smit^{2,6}, Gerrit A. Meijer¹ and Kim

6 Monkhorst¹

7

⁸ ¹Department of Pathology, Division of Diagnostic Oncology, ²Department of Thoracic Oncology, ⁹ Division of Medical Oncology, ³Department of Biometrics, Netherlands Cancer Institute, Amsterdam, ¹⁰ The Netherlands, ⁴Current address: Department of Pulmonary Diseases, Radboud University Medical ¹¹ Center, Nijmegen, The Netherlands, ⁵Division of Molecular Oncology and Immunology, Netherlands ¹² Cancer Institute, Amsterdam, The Netherlands, ⁶Current address: Department of Pulmonary ¹³ Diseases, Leiden University Medical enter, Leiden, The Netherlands.

14

15 **Corresponding authors:**

- 16 Email: <u>k.monkhorst@nki.nl (KM)</u> and <u>k.hummelink@nki.nl</u> (KH)
- 17
- 18
- 19
- 20
- 21
- 22

- 23
- 24

25 Abstract

26 Background

Treatment with PD-(L)1 blocking agents has demonstrated durable efficacy in advanced NSCLC, but only in a minority of patients. Multiple biomarkers for predicting treatment benefit have been investigated, but their combined performance has not been extensively studied. Here, we assess the combined predictive performance of multiple biomarkers in a series of NSCLC patients treated with nivolumab.

32

33 <u>Methods</u>

Pretreatment samples from 135 patients treated with nivolumab were used to assess the predictive performance of CD8 tumor-infiltrating lymphocytes (TILs), intratumoral (IT) localization of CD8 TILs, PD-1 high expressing TILs (PD1^T TILs), CD3 TILs, CD20 Bcells, tertiary lymphoid structures (TLS), PD-L1 tumor proportion score (TPS) and the Tumor Inflammation score (TIS). Patients were assigned to a training (n=55) and validation set (n=80). The primary outcome measure was Disease Control at 6 months (DC 6m) and the secondary outcome measure was DC at 12 months (DC 12m).

41

42 <u>Results</u>

In the validation cohort, the two best performing composite biomarkers (i.e. CD8+IT-CD8 and CD3+IT-CD8) demonstrated similar or lower sensitivity (64% and 83%) and NPV (76% and 85%) than the individual biomarkers PD-1^T TILs and TIS (sensitivity: 72% and 83%, NPV: 86% and 84%) for DC 6m, respectively. Also, at 12 months, both selected composite biomarkers (CD8+IT-CD8 and CD8+TIS) showed less predictive performance

48	compared to PD-1 ^{T} TILs and TIS alone. PD-1 ^{T} TILs and TIS showed high sensitivity (86%
49	and 100%) and NPV (95% and 100%) for DC 12m. PD-1 ^{T} TILs could better discriminate
50	patients with no long-term benefit, since specificity was substantially higher as compared
51	to TIS (74% versus 39%).
52	
53	Conclusion
54	Composite biomarkers did not show improved predictive performance compared to PD-
55	1^{\intercal} TILs and TIS alone for both the 6- and 12-months endpoint. PD- 1^{\intercal} TILs and TIS
56	identified patients with DC 12m with high sensitivity. Patients with no long-term benefit to
57	PD-1 blockade were most accurately identified by PD-1 [⊤] TILs.
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	

71 Introduction

72 The success of monoclonal antibodies targeting the inhibitory receptor programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-73 74 L1) has changed the treatment landscape of advanced stage non-small cell lung cancer 75 (NSCLC). A subset of patients treated with these PD-(L)1 blocking agents can achieve 76 durable responses and gain a large survival benefit (1-7). Unfortunately, the majority does 77 not derive durable clinical benefit, highlighting the need for predictive biomarkers to 78 support treatment decision making in clinical practice. Specifically, biomarkers to exclude 79 patients who are unlikely to benefit from PD-1 blockade therapy can offer patients 80 alternative treatment options.

81 Tumor PD-L1 expression, as detected by immunohistochemistry (IHC), has been 82 studied as a predictive biomarker in multiple clinical trials(8). A positive correlation 83 between PD-L1 expression and treatment outcome has been reported in advanced stage NSCLC patients(1,5-7). However, approximately 60% to 70% of patients with PD-L1 84 85 positive tumors do not respond(1,2,5). Besides this, PD-L1 assessment by IHC is 86 hampered by intratumor heterogeneity, interassay- and interobserver variability as well 87 as pre-analytical variation(9–14). Tumor Mutation Burden (TMB), reflecting the number 88 of somatic mutations as a surrogate of potential tumor antigenicity, has also shown 89 predictive potential but clinical implementation remains challenging due to the lack of a 90 robust and predictive TMB cut-off and the technical issues that arise due to variation 91 across platforms(15–17).

92 For these reasons there is an urgent need for biomarkers that can more accurately 93 predict response to PD-(L)1 blockade in advanced NSCLC. Since PD-(L)1 blockade is

94 thought to reinvigorate tumor-reactive T cells(18–20), several T cell markers have been investigated. For example, the density of CD8⁺ tumor infiltrating lymphocytes (TILs) has 95 96 been correlated to response to PD-(L)1 blockade in melanoma(18), colorectal cancer(21), 97 and NSCLC(22,23). In previous work we have shown that a distinct T cell population, 98 termed PD-1^{\intercal} TILs, can predict clinical benefit in NSCLC(24,25). Notably, these PD-1^{\intercal} 99 TILs predominantly localize in tertiary lymphoid structures (TLS)(24). B cells, which are a 100 critical component of these TLS, have also been linked to response to PD-(L)1 blocking 101 agents(26–28). Other studies developed predictive RNA expression signatures, such as 102 the "tumor inflammation signature" (TIS), to characterize features of immune activity in 103 the tumor microenvironment (TME)(29-31).

104 Although all of these biomarkers have shown a certain predictive potential, their 105 accuracy is still limited which is presumably caused by multiple components that are 106 involved in the antitumor immune response. Hence, combining biomarkers could potentially improve their predictive accuracy, as previously has been shown for the 107 108 combination of TMB with PD-L1(32,33) and CD8 TILs with PD-L1(22,34). Therefore, the 109 aim of the present study was to investigate the performance of CD8, PD-1^T TILs and CD3 110 TILs, CD20⁺ B cells, TLS, PD-L1 and TIS as pairs of biomarkers, compared to single 111 biomarkers, for prediction of clinical benefit to PD-1 blockade in NSCLC.

112

113 Methods

114 *Patients, endpoints and samples*

In this study, 162 patients with pathologically confirmed stage IV NSCLC were eligible for efficacy analysis. All patients started second or later line monotherapy

117 nivolumab, 3mg/kg as an IV infusion every two weeks for at least one dose, between October 2014 and August 2017 at the Netherlands Cancer Institute/Antoni van 118 Leeuwenhoek hospital (NKI-AVL), The Netherlands. Patients with tumors harboring 119 120 known sensitizing EGFR mutations or ALK translocations were excluded from treatment. 121 Patients were randomized into a training and validation cohort. Randomization was 122 stratified by treatment outcome at 6 months and at 12 months. Since we could only 123 generate gene expression data in 68/162 (42%) of patients' tumors, additional 124 stratification was done by whether mRNA expression analysis was performed or not. 125 Stratification for missing values of other biomarkers was not performed, as the number of 126 excluded samples per biomarker was low (range 1 to 32) (see Supplementary Fig. S1 127 and later in this section).

Response was assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients with progressive disease (PD) who were not evaluable for response were determined by the treating physician as PD. The primary clinical outcome was Disease Control (DC) (complete response (CR)/partial response (PR) or stable disease (SD)) at 6 months following initiation of treatment. DC 12m (CR/PR/SD that lasted \geq 12 months) was used as secondary outcome measure to predict long-term efficacy to PD-1 blockade.

Pretreatment formalin-fixed paraffin embedded (FFPE) tumor tissue samples were collected from all patients. Written informed consent was obtained from all patients for research usage of material not required for diagnostic use by institutionally implemented opt-out procedure. The study was conducted in accordance with the Declaration of Helsinki. The data was accessed for research purposes after the approval of the

140 Institutional Review Board (IRB) of the Netherlands Cancer Institute on January 11, 2018 (CFMPB586). After K.H., M.M., R.D.S., M.M.H., E.F.S. and K.M. retrieved archived tumor 141 142 samples and response data from medical records, all patients were pseudonymized. PD-143 1^T TIL and PD-L1 tumor proportion score (TPS) data for 94 samples were used from our 144 previous work as well as tertiary lymphoid structures (TLS) and CD20⁺ B cell data for 91 145 samples (25). In 27 patients, none of the biomarkers could be assessed because samples did not contain tumor tissue. In one sample no tumor tissue was left for CD8 and PD-1^T 146 TIL analysis, as well as in five samples for CD3 TIL, TLS and CD20⁺ B cell analysis 147 148 (Supplementary Fig. S1). An additional number of 32 patients were excluded for PD-1^T 149 TIL analysis based on the following criteria: samples contained less than 10,000 cells 150 (n=12), were obtained from endobronchial lesions (n=16), contained abundant normal 151 lymphoid tissue (n=1) and showed fixation and/or staining artefacts (n=2) (Supplementary Fig. S1). As described before, we excluded bronchial biopsies because 152 153 they frequently showed unspecific antibody staining due to mechanical damage, and 154 lymph node resections due to presence of PD-1⁺ T cells in normal abundant lymphoid 155 tissue, which could potentially lead to false positive results (25). One sample was excluded 156 for CD8 TIL, CD3 TIL, TLS, CD20⁺ B cell and PD-L1 analysis because of fixation/staining artefacts. One sample contained less than 2,000 cells and was excluded for CD8 TIL, 157 158 CD3 TIL, TLS and CD20⁺ B cell analysis. 67 patients (41%) were excluded for mRNA 159 expression analysis because of low RNA yield and/or low RNA quality (Supplementary 160 Fig. S1).

161

162 Immunohistochemistry

163 CD8 immunostaining of samples was performed on a BenchMark Ultra autostainer Instrument (Ventana Medical Systems) on 3 µm paraffin sections from FFPE blocks. 164 165 Sections were initially baked at 75°C for 28 minutes and deparaffinised in the instrument 166 with EZ prep solution (Ventana Medical Systems). Heat-induced antigen retrieval was carried out using Cell Conditioning 1 (CC1, Ventana Medical Systems) for 32 minutes. 167 168 CD8 was detected using clone C8/144B (1/200 dilution, 32 minutes at 37°C, Agilent/DAKO). Bound antibody was detected using the OptiView DAB Detection Kit 169 170 (Ventana Medical Systems). Slides were counterstained with Hematoxylin and Bluing 171 Reagent (Ventana Medical Systems).

PD-1 immunostaining was detected using clone NAT105 (Roche Diagnostics), PD-L1 using clone 22C3 (Agilent/DAKO) and CD68 using clone KP1 (Agilent/DAKO). For the double staining CD20 (yellow) followed by CD3 (purple) we used clone L26 (Agilent/DAKO) (CD20) and clone SP7 (Thermo Fisher) (CD3). All immunostainings were performed as described previously(25).

177 CD8, PD-1, PD-L1 and CD68 immunostainings were scanned at x20 magnification 178 with a resolution of 0.50 per μ m² using an Aperio slide AT2 scanner (Leica Biosystems). 179 CD20-CD3 immunostainings were scanned at x20 magnification with a resolution of 0.24 180 per μ m² using a 3Dhistech P1000 scanner. PD-L1 and CD68 data were uploaded on Slide 181 Score, a web platform for manual scoring of digital slides using a scoring sheet 182 (www.slidescore.com).

183

184 Digital quantification of CD8 and PD-1^T TILs

185 Digital image analysis was performed by a trained MD (K.H.) and supervised by an experienced pathologist (K.M.) using the Multiplex IHC v1.2 module from the HALO[™] 186 187 image analysis software, v2.3.2089.69 (Indica Labs). Researchers were blinded for 188 clinical outcome. Classification of CD8 lymphocytes on single stains was performed using 189 a computationally derived cut-off of 0.3 optical density (OD), which reflects the intensity 190 of the staining. This cut-off was identified by manually optimizing the detection of CD8 191 positive stained cells in FFPE samples. An image analysis algorithm utilizing a cut-off of 192 0.3 OD was generated for automated analyses of CD8 lymphocytes in subsequent FFPE 193 samples. The quantification of PD-1^T TILs was performed as described previously(25).

The number of CD8 and PD-1^T TILs per mm² tumor area were determined. Tumor areas were digitally annotated as described previously(25). PD-1^T TIL data of 94 samples were used from previous work(25). For regional analysis of CD8 lymphocytes, classifiers were trained to identify stromal and tumoral regions in which the CD8 lymphocytes were quantified separately. The percentage CD8 lymphocytes in tumoral regions (i.e. intratumoral (IT)) compared to total CD8 TILs was calculated **(Supplementary Table S1)**.

200

201 Scoring of tertiary lymphoid structures

The HALO[™] image analysis software, v2.3.2089.69 (Indica Labs) was used to determine the number of TLS and the combined number of TLS and lymphoid aggregates (TLS+LA) per mm² tumor area on a CD20-CD3 double immunostaining as described previously(25). TLS and TLS+LA data of 91 samples were used from previous work(25) (Supplementary Table S1).

207

208 CD20 and CD3 quantification by digital image analysis

209 The total area with CD20 expression was measured using a previously generated 210 image analysis algorithm from the Area Quantification v1.0 module of HALO[™] image 211 analysis software (Indica Labs)(25). The same algorithm was used to measure the total 212 area with CD3 expression. The CD20-positive and CD3-positive area were normalized 213 per mm² tumor area. Cell numbers were not guantified as no reliable algorithm could be established due to dense clustering of CD20⁺ or CD3⁺ cells in and at the border of TLS. 214 215 Tumor areas were digitally annotated as described previously(25). CD20 data of 91 216 samples were used from previous work(25) (Supplementary Table S1).

217

218 PD-L1 scoring

219 PD-L1 TPS was determined using the qualitative, clinical grade LDT IHC assay 220 (22C3 Agilent/DAKO) as described previously(25). PD-L1 TPS data of 94 samples were 221 used from previous work(25) (**Supplementary Table S1**). The CD68 staining was 222 compared to the PD-L1 staining to exclude macrophages that are both CD68⁺ and PD-223 L1⁺ which can introduce false positive results.

224

225 RNA extraction and hybridization to nCounter tagset

226 RNA of pretreatment FFPE samples from the NKI-AVL cohorts were isolated with 227 the AllPrep DNA/RNA FFPE isolation kit (#80234, Qiagen) according to the instructions 228 of the manufacturer and quantified by Tapestation (Agilent). 200 to 300 ng RNA were 229 hybridized to Nanostring PanCancer IO 360 Panel code set (Nanostring), according to 230 the recommendations of the manufacturer. After hybridization non-bound probes were

washed off and the RNA-probe complex was bound to the cartridge on the Nanostring
Flex Prep Station according to manufacturing protocol. The cartridge was sealed and
transferred to the Digital Analyzer for imaging.

234

235 Statistical analysis

Patient characteristics were descriptively reported using mean \pm SD, interquartile range (IQR) or frequencies (percentages). The Mann-Whitney test for continuous data, Fisher's exact test for categorical data and linear-by-linear association test for ordinal data were used to assess differences in patient characteristics between cohorts (training and validation) and between outcome groups (disease control vs PD). Differences were considered statistically significant if **P*<0.05, ***P*<0.01, ****P*<0.001 or *****P*<0.0001.

Genes in the Tumor Inflammation Signature (TIS) are normalized using a ratio of the expression value to the geometric mean of the housekeeper genes used only for the TIS signature and then followed by log2 transformation. The TIS score was calculated as a weighted linear combination of the 18 gene expression values(29,35) (**Supplementary Table S1**). This analysis was performed by Nanostring as part of their intellectual property.

In the training cohort, univariate models and bivariate logistic models for DC 6m and DC 12m of treatment were constructed using CD8 TILs, IT-CD8 T cells, PD-1^T TILs, CD3 TILs, TLS, TLS+LA, CD20⁺ B cells, PD-L1 and TIS. The bivariate models included an interaction term. The bivariate logistic model produces for each patient a number between 0 and 1, reflecting the probability (according to the model) of patients reaching DC 6m or DC 12m. Calculation of the area under the receiver operating characteristic (ROC) curve was used as a measure of discriminatory ability. The predictive performance of different individual and composite biomarkers on the same patient population was described in terms of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and compared using the McNemar test. A point on the ROC curve matching a sensitivity of 90% for DC 6m and 90% for DC 12m was selected to calculate corresponding specificity, NPV and PPV. We further aimed for an NPV of ≥90% and a specificity of ≥50%.

Two (closely related) non-parametric approaches were considered to obtain 90% 261 262 sensitivity for predicting DC 6m and DC 12m from two biomarkers: by choosing a cutpoint for each of the two biomarkers and declaring the patient positive (i.e. likely to 263 264 respond to PD-1 blockade) when either at least one (first method) or both (second 265 method) biomarker values were above their respective cut-point values. The specificities obtained were either equal or worse to those obtained by the parametric method 266 267 described above (i.e. via logistic regression). Therefore, these non-parametric methods 268 were not used in this study.

Four training models were selected with a cut-off that showed the highest specificity and NPV at the prespecified sensitivities for prediction of DC 6m and DC 12m. This cut-off was used to determine sensitivity, specificity, NPV and PPV in the validation cohort.

273

274 Results

275 Biomarker characteristics and demographics

276 To assess the predictive performance of multiple biomarker combinations we first 277 analyzed 162 pretreatment tumor samples from 162 advanced stage NSCLC patients 278 treated with nivolumab. In total we evaluated 9 biomarkers: (1) the total number of CD8 279 TILs per mm², (2) the percentage intra-tumoral (IT) CD8 T cells of total CD8 TILs, (3) the number of PD-1^T TILs per mm² (4) the CD3-positive area per mm² to estimate the 280 presence of CD3 TILs (5) the CD20-positive area per mm² to estimate the presence of B 281 cells (6) the number of TLS and (7) the combined number of TLS and LA (referred as 282 TLS+LA) per mm², (8) the PD-L1 Tumor Proportion Score (TPS) and (9) the TIS score 283 284 (NanoString) (Fig. 1). We could successfully assess CD8 TILs and IT-CD8 T cells in 285 132/162 (81%), PD-1^T TILs in 103/162 (64%), CD3 TILs, CD20⁺ B cells, TLS and TLS+LA in 128/162 (79%), PD-L1 TPS in 134/162 (83%) and TIS in 68/162 (42%) samples (Table 286 287 1, Supplementary Fig. S1). Sample exclusion criteria are shown per biomarker in Supplementary Fig. S1. 288

289 We randomized patients with ≥ 2 biomarker results available (n=135) in a training 290 (n=55) and validation (n=80) cohort. This randomization was stratified for clinical benefit 291 to ascertain that in both cohorts 1 in 3 patients reached DC 6m and 1 in 5 patients reached 292 DC 12m, respectively. Since a limited number of patients with TIS scores (n=68) were 293 available, these patients were randomly distributed proportionately (Table 1, 294 Supplementary Fig. S1). For every patient the results per biomarker are shown in 295 **Supplementary Table S1**. Demographic characteristics did not significantly differ among 296 the training and validation cohort (Table 2).

297

298 Accuracy of individual and composite biomarkers to predict DC at 6 months

299 Next, we determined the most optimal cut-offs for each individual and composite 300 biomarkers in the training cohort. We aimed for a sensitivity and NPV of ≥90% to minimize 301 undertreatment and a specificity of at least 50% to identify those patients that are unlikely 302 to respond to PD-1 blockade therapy and can potentially benefit from alternative 303 treatments. Since not all tumor samples were evaluable for all nine biomarkers, the 304 number of training samples ranged from 28 to 55 (Table 1, Supplementary Fig. S1). In total, 16 composite biomarkers and PD-1^T and TIS as individual biomarkers reached 305 ≥90% sensitivity and ≥50% specificity (Supplementary Table S2). Interestingly, these 306 307 include 7/8 (88%) possible combinations with PD-1^T TILs and 5/8 (63%) with TIS 308 (Supplementary Table S2). However, none of these combinations did significantly improve predictive accuracy compared to PD-1^T TILs and TIS alone (Supplementary 309 310 Fig. S2A,B) and were excluded from further analysis.

311 Next, we selected the four remaining biomarkers with the highest predictive 312 performance for validation, being the combinations of CD8+IT-CD8 and CD3+IT-CD8, as 313 well as PD-1^T TILs and TIS alone, respectively (Supplementary Table S2). In the training 314 cohort, both CD8+IT-CD8 and CD3+IT-CD8 had significantly higher probability scores in 315 the DC 6m group (reflecting the probability of patients reaching DC 6m) compared to the PD group (CD8+IT-CD8, P<0.0001 and CD3+IT-CD8, P<0.001) (Fig. 2A,B). The area 316 317 under the ROC curve (AUC) was 0.83 (95% CI 0.73-0.94) for CD8+IT-CD8, and 0.78 318 (95% CI 0.65-0.92) for CD3+IT-CD8 (Fig. 2C,D). Cut-offs of 0.167 and 0.161, 319 respectively, correlated to a sensitivity of 94% and 94%, specificity of 62% and 54%, NPV 320 of 96% and 95% and PPV of 50% and 47% (Table 3).

321 Also, the PD-1^T TIL numbers and TIS scores were significantly higher in the DC 6m group than in the PD group (PD-1^T TILs, P<0.001 and TIS, P<0.01) (Supplementary 322 323 Fig. S2C,D). PD-1^T TILs showed an AUC of 0.82 (95% CI 0.69-0.95) and TIS an AUC of 324 0.81 (95% CI 0.65-0.98) (Supplementary Fig. S2E,F). For PD-1^T TILs a cut-off of 90 per 325 mm^2 was chosen, as this cut-off showed predictive value in a prior study(25). We 326 observed a sensitivity of 92%, specificity of 67%, NPV of 95% and PPV of 52% (Table 327 **3)**. A score of 6.65 was chosen as optimal cut-off for TIS which correlated to a sensitivity of 100%, specificity of 55%, NPV of 100% and PPV of 47% (Table 3). 328

329 Next, we evaluated the predictive performance of the four selected biomarkers in 330 the validation cohort. The number of validation samples with successful biomarker results 331 ranged from 40 to 79 (Table 1, Supplementary Fig. S1). We observed that the predictive 332 accuracy of CD8+IT-CD8 and CD3+IT-CD8 biomarkers was substantially lower 333 compared to the training cohort. Specifically, probability scores in the DC 6m group did 334 not significantly differ from scores in the PD group for CD8+IT-CD8 (P=0.08) (Fig. 2E). 335 For CD3+IT-CD8 this comparison was borderline significant (P=0.01) (Fig. 2F). The AUC 336 of the ROC curve was 0.62 (95% CI 0.50-0.75) for CD8+IT-CD8 and 0.68 (95% CI 0.55-337 0.80) for CD3+IT-CD8 (Fig. 2C,D). CD8+IT-CD8 reached a sensitivity of 64%, specificity of 56%, NPV of 76% and PPV of 41%. The predictive accuracy of CD3+IT-CD8 was 338 339 higher than CD8+IT-CD8 but still lower than in the training cohort, reaching a sensitivity 340 of 83%, specificity of 46%, NPV of 85% and PPV of 43% (Table 3).

The individual biomarkers in the validation cohort showed that PD-1^T TIL numbers were significantly higher in the DC 6m group versus the PD group (*P*<0.01), which was not observed for TIS scores (*P*=0.52) (**Supplementary Fig. S2G,H**). The discriminatory

344 ability of PD-1^T TILs was lower as in the training, but still reached an AUC of 0.72 (95% CI 0.57-0.87) (Supplementary Fig. S2E). TIS reached an AUC of 0.57 (95% CI 0.36-345 0.77) (Supplementary Fig. S2F). A cut-off of 90 PD-1^T TILs per mm² correlated to a 346 sensitivity of 72%, specificity of 74%, NPV of 86% and PPV of 54%. A TIS score of 6.65 347 showed a comparable sensitivity (83%), NPV (84%) and PPV (37%) but lower specificity 348 349 (39%) (Table 3). In summary, these results demonstrate that a combination of CD8+IT-CD8 and CD3+IT-CD8 did not improve predictive accuracy compared to PD-1^T TILs and 350 351 TIS alone. Furthermore, none of the selected biomarkers reached the prespecified 352 performance criteria.

353

354 Accuracy of individual and composite biomarkers to predict DC at 12 months

355 Approximately 70-80% of patients treated in 2nd line with PD-(L)1 blockade progress within 12 months(2–4). We previously demonstrated that PD-1^T TILs could more 356 357 effectively identify patients with DC 12m as compared to DC 6m, as well as a patient group without long-term benefit(25). We therefore also assessed the performance of all 358 359 biomarkers to predict DC 12m. Similar to the DC 6m analysis, we determined the most 360 optimal cut-offs for each of the composite and individual biomarkers to identify patients 361 with DC 12m and with PD. Four patients in the training and nine patients in the validation 362 experienced disease progression between 6 and 12 months, and were therefore included 363 in the PD group in this analysis. 16 composite biomarkers reached ≥90% sensitivity and \geq 50% specificity in the training cohort, as well as PD-1^T TILs and TIS as individual 364 365 biomarkers (Supplementary Table S3). We observed that 12/16 composite and 2/2 366 individual biomarkers (PD-1^T TILs and TIS), matched the 6-months endpoint with similar

367 accuracy (Supplementary Table S2,3). PD-1^T TIL combinations did not significantly improve predictive accuracy compared to PD-1^T TILs alone and were excluded from 368 369 further analysis (Supplementary Fig. S3A, Supplementary Table S3). However, the 370 combination of CD8 with TIS (CD8+TIS) showed an increase of 18% specificity compared 371 to TIS alone. This combination was selected for further analysis, even though it did not 372 reach statistical significance, possibly due to the low sample size (P=0.34) (Supplementary Fig. S3B, Supplementary Table S3). The four biomarkers with the 373 highest predictive performance were selected for validation. 3/4 selected biomarkers, 374 375 including PD-1^T TILs, TIS and CD8+IT-CD8, matched the DC 6m selection. The fourth 376 biomarker included the combination of CD8+TIS (Supplementary Table S3).

377 The probability scores for DC 12m and PD are shown per sample in 378 Supplementary Fig. S3C (CD8+IT-CD8, P<0.001) and Supplementary Fig. S3D 379 (CD8+TIS, P<0.01). The two composite biomarkers showed a high AUC of 0.85 (95% CI: 380 0.73-0.96) (CD8+IT-CD8) and 0.91 (95% CI: 0.79-1.00) (CD8+TIS) in the training cohort 381 (Fig. 3A,B). A cut-off of 0.122 and 0.124, respectively, was chosen as optimal cut-off 382 (Table 3). PD-1^T TIL numbers and TIS scores are shown in **Supplementary Fig S3E** and **F**. A cut-off of 90 PD-1^T TILs per mm² and a TIS score of 6.65 demonstrated similar 383 predictive accuracy as in the training for DC 6m (Fig. 3C,D, Table 3). 384

In the validation cohort, of the two composite biomarkers, only CD8+IT-CD8 showed borderline significantly higher probability scores in the DC 12m group versus the PD group (*P*=0.03) (**Supplementary Fig. S3G,H**). The ROCs yielded low AUCs (CD8+IT-CD8: 0.67 (95% CI: 0.53-0.81), CD8+TIS: 0.59 (95% CI 0.36-0.81)) (Fig 3A,B). Furthermore, the sensitivity (68% and 29%), specificity (57% and 68%), NPV (88% and

390 81%) and PPV (30% and 17%) did not meet the prespecified performance criteria (Table
391 3).

392 PD-1^T TIL numbers were significantly higher in patients with DC 12m versus PD 393 (P<0.001) (Fig. 3E). PD-1^T TILs also demonstrated a consistently high AUC (0.80, 95%) 394 CI: 0.65-0.94) and high accuracy, reaching a sensitivity of 86%, specificity of 74%, NPV 395 of 95% and PPV of 50% (Fig. 3C, Table 3). We observed an enrichment of patients with 396 DC 12m in the ≥90 group and with PD in the <90 subgroup (Fig. 3E). TIS scores did not significantly differ between the two groups (P=0.31) and showed a low AUC of 0.63 (95%) 397 398 CI 0.43-0.82) (Fig. 3D,F). However, a cut-off score of 6.65 reached a sensitivity of 100%, 399 specificity of 39%, NPV of 100% and PPV of 26% (Table 3). These findings did not meet 400 our \geq 50% specificity criterium, but accurately identified all patients with DC 12m including 401 39% of patients with PD (Fig. 3F). Taken together, PD-1^T TILs and TIS as individual 402 biomarkers showed higher predictive accuracy for DC 12m compared to the combination of CD8+IT-CD8 and CD8+TIS. Notably, PD-1^T TILs alone was more accurate than TIS 403 404 alone, as specificity and PPV were substantially higher.

405

406 **Discussion**

Since the introduction of PD-(L)1 blockade therapy, clinical outcome of advanced stage NSCLC has dramatically improved. Nevertheless, a subset of patients derive benefit from these treatments which consequently has led to overtreatment and unnecessarily side effects in many. In addition, health care systems deal with increasing costs. Several predictive biomarkers have been identified to support treatment decision making. Since different components in the TME can affect the tumor immune response

413 upon PD(L)1 blockade therapy, it is unlikely to find one single perfect biomarker. Based 414 on the hypothesis that a predictive model should contain more than one biomarker; we 415 here assess the predictive performance of biomarker combinations in an advanced stage 416 NSCLC cohort treated with nivolumab. Our data showed that selected composite 417 biomarkers did not improve predictive performance as compared to PD-1^T TILs and TIS 418 alone. At 6 months, none of the selected composite and individual biomarkers reached the prespecified performance criteria in the validation cohort. At 12 months, PD-1^T TILs 419 and TIS could identify patients with DC 12m with high accuracy. Patients without long-420 421 term benefit were more accurately identified by PD-1^T TILs than TIS.

422 Whereas CD8 or CD3 TILs in combination with intratumoral localization of CD8 T 423 cells were the most accurate composite biomarkers for DC 6m in the training cohort, we 424 observed that discriminatory ability was low in the validation cohort. The presence and 425 localization of TILs alone might not indicate that all T cells are in a state to recognize and 426 eliminate the tumor (36,37). In the present study, this notion is supported by the high 427 accuracy of PD-1^T TILs to predict DC 12m, as these TILs have been identified as a distinct 428 TIL subset with a high capacity of tumor recognition(24). The results are similar to our 429 previous work because the majority of samples were re-used(25). Further refinement of 430 this T cell population could contribute to the development of new markers or gene 431 signatures, as recently been done by other studies (38–40). Since most of the biomarkers 432 assessed in this study are related to antitumor immunity and are presumably correlated, 433 PD-1^T combinations did not improve specificity.

434 Previous studies have shown the predictive potential of combining CD8+PD-435 L1(22,34). However, in our training cohort, CD8+PD-L1 did not meet our performance

436 criteria, and as a result, this combination was not further evaluated. Noguchi et al. 437 previously observed that PD-L1 expression on tumor cells is transient and dependent on 438 the production of IFNy by TILs(41). Hence, variable tumor PD-L1 expression in training 439 samples might have affected the predictive accuracy of PD-L1 alone and that of PD-L1 440 combinations. Furthermore, this study is limited by the number of samples, in particularly 441 for TIS assessment. Therefore, we restricted our evaluation to two-biomarker 442 combinations instead of considering three or more. Studies involving a larger number of 443 samples are essential to further validate our findings.

444 Our results for TIS are in line with other studies that demonstrated the predictive potential of this signature (29,42). Interestingly, TIS contains genes that are highly 445 446 expressed in PD-1^T TILs, such as LAG3 and TIGIT(24,29). A high number of PD-1^T TILs or a high TIS score in pretreatment samples may serve as surrogate markers for a tumor's 447 448 ability to undergo durable immune reactivation upon PD-1 blockade therapy. A PD-1^T 449 TILs or TIS combination with biomarkers reflecting distinct parts of the immune response 450 could potentially improve predictive accuracy. For example, TMB can serve as a read-out 451 for immunogenic neoantigens that arise from somatic mutations(15). TMB and PD-L1 452 have previously been described as independent predictors for advanced NSCLC treated 453 with PD-1 blockade and have shown improved performance when combined(32,33). Another suggestion is, in contrast, the presence of tumor-resident regulatory T cells (T_{reg}) 454 in the TME. T_{reg} cells possess an immune-inhibitory function and high numbers are 455 correlated to poor patient survival(43). A combination of TMB or T_{req} with either PD-1^T or 456 TIS could be further explored in future work. 457

- 458 In conclusion, this study showed that the biomarker combinations assessed here
- 459 did not improve predictive performance when compared to PD-1^T TILs and TIS alone.
- 460 PD-1^T TILs showed the highest predictive performance of all biomarkers, as patients with
- 461 no long-term benefit were identified with high specificity and NPV.
- 462

463 **Acknowledgements**

We would like to thank the NKI-AVL Core Facility Molecular Pathology and Biobanking for supplying all IHC stainings used in this study, as well as biobank-related work and other laboratory support.

467

468 **References**

- 469 1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al.
- 470 Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung
- 471 Cancer. N Engl J Med. 2016;375(19):1823–33. Available from:
- 472 http://www.nejm.org/doi/10.1056/NEJMoa1606774
- 473 2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al.
- 474 Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung
- 475 cancer. N Engl J Med. 2015;373(17):1627–39.
- 476 3. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al.
- 477 Atezolizumab versus docetaxel in patients with previously treated non-small-cell
- 478 lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

479 Lancet. 2017;389(10066):255–65.

480 4. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al.

- 481 Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung
 482 cancer. N Engl J Med. 2015;373(2):123–35.
- 483 5. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al.
- 484 Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med.
- 485 **2015;372(21):2018–28**.
- 486 6. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al.
- 487 Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based
- 488 chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor
- 489 proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46.
- 490 7. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five-
- 491 year overall survival for patients with advanced non-small-cell lung cancer treated
 492 with pembrolizumab: Results from the phase i KEYNOTE-001 study. J Clin Oncol.
- 493 2019;37(28):2518–27.
- Peters S, Reck M, Smit EF, Mok T, Hellmann MD. How to make the best use of
 immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung
 cancer. Ann Oncol. 2019;30(6):884–96.
- 497 9. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative
- 498 study of the PD-L1 status between surgically resected specimens and matched
- 499 biopsies of NSCLC patients reveal major discordances: A potential issue for anti-
- 500 PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–53. Available from:
- 501 https://doi.org/10.1093/annonc/mdv489
- 502 10. Gniadek TJ, Li QK, Tully E, Chatterjee S, Nimmagadda S, Gabrielson E.
- 503 Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and

adenocarcinoma: Implications for assessment by small biopsy. Mod Pathol.

505 2017;30(4):530–8.

- 506 11. Boothman AM, Scott M, Ratcliffe M, Whiteley J, Dennis PA, Wadsworth C, et al.
- 507 Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell
- 508 Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC
- 509 Screened for the ATLANTIC Study. J Thorac Oncol. 2019;14(8):1390–9.
- 510 12. Hong L, Negrao M V., Dibaj SS, Chen R, Reuben A, Bohac JM, et al.
- 511 Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From
- 512 Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020;15(9):1449–59.
- 513 Available from: https://doi.org/10.1016/j.jtho.2020.04.026
- 13. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman
- 515 J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-

small-cell lung cancer. JAMA Oncol. 2016;2(1):46–54.

- 517 14. Butter R, A'T Hart N, Hooijer GKJ, Monkhorst K, Speel EJ, Theunissen P, et al.
- 518 Multicentre study on the consistency of PD-L1 immunohistochemistry as
- 519 predictive test for immunotherapy in non-small cell lung cancer. J Clin Pathol.

520 **2020;73(7):423–30**.

- 521 15. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al.
- 522 Mutational landscape determines sensitivity to PD-1 blockade in non-small cell 523 lung cancer. Science (80-). 2015;348(6230):124–8.
- 524 16. Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, et al.
- 525 First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer
- 526 (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational

527 burden as biomarkers. J Clin Oncol. 2019;37(12):992–1000.

- 528 17. Sholl LM, Hirsch FR, Hwang D, Botling J, Lopez-Rios F, Bubendorf L, et al. The
- 529 Promises and Challenges of Tumor Mutation Burden as an Immunotherapy
- 530 Biomarker: A Perspective from the International Association for the Study of Lung
- 531 Cancer Pathology Committee. J Thorac Oncol. 2020;15(9):1409–24.
- 532 18. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al.
- 533 PD-1 blockade induces responses by inhibiting adaptive immune resistance.
- 534 Nature. 2014;515(7528):568–71.
- 535 19. van der Leun AM, Thommen DS, Schumacher TN. CD8+ T cell states in human
- 536 cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–32.

537 Available from: http://dx.doi.org/10.1038/s41568-019-0235-4

538 20. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell

539 invigoration to tumour burden ratio associated with anti-PD-1 response. Nature.

- 540 2017;545(7652):60–5.
- 541 21. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1
- 542 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med.
- 543 2015;372(26):2509–20.
- 544 22. Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, et al.
- 545 Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor
- 546 tissue of patients under anti-PD-1 therapy. Br J Cancer. 2018;119(8):950–60.
- 547 Available from: http://dx.doi.org/10.1038/s41416-018-0220-9
- 548 23. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, et al.
- 549 Tumor characteristics associated with benefit from pembrolizumab in advanced

550 non–small cell lung cancer. Clin Cancer Res. 2019;25(16):5061–8.

- 551 24. Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A
- 552 transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive
- 553 potential in non-small-cell lung cancer treated with pd-1 blockade. Nat Med.
- 554 2018;24(7). Available from: http://dx.doi.org/10.1038/s41591-018-0057-z
- 555 25. Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, et
- al. PD-1^T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in
- 557 patients with advanced NSCLC. Clin Cancer Res. 2022;(10):1–14. Available from:
- 558 http://www.ncbi.nlm.nih.gov/pubmed/35852792
- 559 26. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary
- 560 lymphoid structures improve immunotherapy and survival in melanoma. Nature.
- 561 2020;(February). Available from: http://www.ncbi.nlm.nih.gov/pubmed/31942071
- 562 27. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and

563 tertiary lymphoid structures promote immunotherapy response. Nature.

- 564 2020;(February). Available from: http://www.ncbi.nlm.nih.gov/pubmed/31942075
- 565 28. Petitprez F, de Reyniès A, Keung EZ, Chen TW-W, Sun C-M, Calderaro J, et al. B
- 566 cells are associated with survival and immunotherapy response in sarcoma.
- 567 Nature. 2020;577(June 2018). Available from:
- 568 http://www.ncbi.nlm.nih.gov/pubmed/31942077
- 569 29. Ayers M, Ribas A, Mcclanahan TK, Ayers M, Lunceford J, Nebozhyn M, et al.
- 570 blockade IFN- γ related mRNA profile predicts clinical response to PD-1
- 571 blockade. J Clin Invest. 2017;127(8):2930–40.
- 572 30. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J,

- 573 et al. Atezolizumab versus docetaxel for patients with previously treated non-
- 574 small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised
- 575 controlled trial. Lancet. 2016;387(10030):1837–46. Available from:
- 576 http://dx.doi.org/10.1016/S0140-6736(16)00587-0
- 577 31. Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, et al.
- 578 Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes
- 579 in patients with non–small cell lung carcinoma or urothelial cancer treated with
- 580 durvalumab. Clin Cancer Res. 2018;24(16):3857–66.
- 581 32. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al.
- 582 Molecular determinants of response to anti-programmed cell death (PD)-1 and
- 583 anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell
- 584 lung cancer profiled with targeted next-generation sequencing. J Clin Oncol.
- 585 2018;36(7):633–41.
- 586 33. Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et
- al. Genomic Features of Response to Combination Immunotherapy in Patients
- 588 with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018;33(5):843-852.e4.
- 589 34. Althammer S, Tan TH, Spitzmüller A, Rognoni L, Wiestler T, Herz T, et al.
- 590 Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1
- therapy. J Immunother Cancer. 2019;7(1):1–12.
- 592 35. Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, et al. Pan-cancer
- ⁵⁹³ adaptive immune resistance as defined by the Tumor Inflammation Signature
- 594 (TIS): Results from The Cancer Genome Atlas (TCGA). J Immunother Cancer.
- 595 2018;6(1):1–17.

- 596 36. Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, et
- al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human
- 598 cancers. Nat Med. 2019;25(1):89–94. Available from:
- 599 http://dx.doi.org/10.1038/s41591-018-0266-5
- 600 37. Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, et al. Bystander
- 601 CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates.
- 602 Nature. 2018;557(7706):575–9.
- 603 38. Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick DT, Le PM, et al.
- 604 Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma.
- 605 Nature. 2021;596(7870):119–25. Available from:
- 606 http://dx.doi.org/10.1038/s41586-021-03704-y
- 607 39. Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EHC, et al. Transcriptional
- programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Vol. 596,
- 609 Nature. Springer US; 2021. 126–132 p. Available from:
- 610 http://dx.doi.org/10.1038/s41586-021-03752-4
- 40. Lowery FJ, Krishna S, Yossef R, Parikh NB, Chatani PD, Zacharakis N, et al.
- 612 Molecular signatures of antitumor neoantigen-reactive T cells from metastatic
- 613 human cancers. Science. 2022;884(February):eabl5447. Available from:
- 614 http://www.ncbi.nlm.nih.gov/pubmed/35113651
- 41. Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, et al. Temporally
- distinct PD-L1 expression by tumor and host cells contributes to immune escape.
- 617 Cancer Immunol Res. 2017;5(2):106–17.
- 42. Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton

- J, et al. The tumor inflammation signature (TIS) is associated with anti-PD-1
- 620 treatment benefit in the CERTIM pan-cancer cohort. J Transl Med. 2019;17(1):1–
- 621 10. Available from: https://doi.org/10.1186/s12967-019-2100-3
- 43. Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the
- 623 not-so-helpful. Cancer Immunol Res. 2014;2(2):91–8.
- 624

625 Figure legends

626 Figure 1. Immunohistochemical analysis of all biomarkers and digital mark-up

627 (A) The left image shows an example of a CD8 immunohistochemical staining (IHC). The black square indicates the area that is shown in the central image. The right image shows 628 629 the digital markup with CD8 TILs (in brown) and all other cells (in grey). (B) The left image 630 shows the same example as shown in A. The black square indicates the area that is shown in the central image. The right image shows regional analysis of only intratumoral 631 632 (IT) CD8 TILs. Stromal CD8 TILs are not quantified. Red lines indicate the tumor region. 633 Red arrows indicate IT-CD8 TILs. White arrow indicates the area with stromal CD8 TILs. 634 (C) The left image shows an example of a consecutive slide stained for PD-1 IHC. The 635 black square indicates the area that is shown in the central image. The right image shows the digital markup with PD-1^T TILs (in brown) and all other cells (in grey). (D) The left 636 637 image shows an example of a consecutive slide double stained with CD20 and CD3 IHC. 638 The black square indicates the area that is shown in the central image with CD20⁺ B cells 639 (in yellow) and CD3⁺ T cells (in purple) localizing in a TLS. The right image shows the 640 digital markup with CD20-positive areas highlighted by the intensity of the yellow staining 641 (depicted as spectrum from yellow to red color). (E) Example of a consecutive slide

stained for PD-L1 IHC. The black square indicates the area that is shown in the rightimage. PD-L1 IHC slides were scored manually.

644

Figure 2. Performance of selected composite and individual biomarkers to predict

646 **DC at 6 months in NSCLC patients treated with PD-1 blockade.**

647 (A) Probability scores of CD8+IT-CD8 in pretreatment samples from patients with disease 648 control at 6 months (DC 6m) (n=16) and progressive disease (PD) (n=39) in the training cohort (n=55). Dashed line indicates a cut-off of 0.167. Medians, interquartile ranges and 649 650 minimum/maximum shown in boxplots, ****P<0.0001 by Mann Whitney U-test. (B) 651 Probability scores of CD3+IT-CD8 in pretreatment samples from patients with DC 6m 652 (n=16) and PD (n=37) in the training cohort (n=53). Dashed line indicates a cut-off of 653 0.161. Medians, interguartile ranges and minimum/maximum shown in boxplots, ***P<0.001 by Mann Whitney U-test. (C) Receiver operating characteristic (ROC) curve 654 655 for predictive value of CD8+IT-CD8 for DC 6m in the training (n=55) (AUC 0.83, 95% CI: 656 0.73-0.94) and validation cohort (n=77) (AUC 0.62, 95% CI: 0.50-0.75). (D) ROC curve for predictive value of CD3+IT-CD8 for DC 6m in the training (n=53) (AUC 0.78, 95% CI: 657 658 0.65-0.91) and validation cohort (n=74) (AUC 0.68, 95% CI: 0.55-0.80). (E) Same plot as in A (CD8+IT-CD8) for patients with DC 6m (n=25) and PD (n=52) in the validation cohort 659 660 (n=77), P=0.08. (F) Same plot as in B (CD3+IT-CD8) for patients with DC 6m (n=24) and 661 PD (n=50) in the validation cohort (n=74), *P=0.02.

662

Figure 3. Performance of selected composite and individual biomarkers to predict
DC at 12 months in NSCLC patients treated with PD-1 blockade.

665 (A) Receiver operating characteristic (ROC) curve for predictive value of CD8+IT-CD8 for disease control at 12 months (DC 12m) in the training cohort (n=55) (AUC 0.85, 95% 666 CI: 0.73-0.96) and validation cohort (n=77) (AUC 0.67, 95% CI: 0.53-0.81). (B) ROC curve 667 668 for predictive value of CD8+TIS for DC 12m in the training cohort (n=28) (AUC 0.91, 95% CI: 0.79-1.00) and validation cohort (n=38) (AUC 0.59, 95% CI: 0.36-0.82). (C) ROC curve 669 for predictive value of PD-1^T TILs for DC 12m in the training cohort (n=42) (AUC 0.82, 670 95% CI: 0.70-0.94) and validation cohort (n=61) (AUC 0.80, 95% CI: 0.65-0.94). (D) ROC 671 curve for predictive value of TIS for DC 12m in the training cohort (n=28) (AUC 0.77, 95% 672 673 CI: 0.58-0.96) and validation cohort (n=40) (AUC 0.63, 95% CI: 0.43-0.82). (E) PD-1^T 674 TILs per mm^2 in pretreatment samples from patients with DC 12m (n=14) and PD (n=47) in the validation cohort (n=61). Dashed line indicates a cut-off of 90 PD1^T TILs per mm². 675 676 Medians, interquartile ranges and minimum/maximum shown in boxplots, $*^{*}P < 0.01$ by Mann Whitney U-test. (F) TIS scores in pretreatment samples from patients with DC 12m 677 678 (n=7) and PD (n=33) in the validation cohort (n=40). Dashed line indicates a cut-off score 679 of 6.65. Medians, interguartile ranges and minimum/maximum shown in boxplots, P=0.31 680 by Mann Whitney U-test.

681

682

683

684

685

686

687

	Total samples (n)			Training (n)			Validation (n)						
Biomarkers		DC 6m	PD (within 6m)	DC 12 m	PD (within 12m)	Total	DC 6m	PD (within 6m)	DC 12m	PD (within 12m)	Total		
CD8 TILs IT-CD8 T cells	132	16	39	12	43	55	25	52	16	61	77		
PD-1 [⊤] TILs	103	12	30	9	33	42	18	43	14	47	61		
CD3 TILs CD20⁺ B cells TLS TLS+LA	128	16	37	12	41	53	24	51	15	60	75		
PD-L1 TPS	134	16	39	12	43	55	25	54	16	63	79		
TIS	68	8	20	6	22	28	12	28	7	33	40		

Table 1. Total number of samples per biomarker in the training and validation cohort.

690 Table 2. Patient characteristics and treatment outcomes for training and validation

691 cohorts. P-values were calculated by Mann-Whitney, Fisher exact or linear-by-linear 692 association tests. S.d, standard deviation; IQR, interguartile range; PS, Performance 693 Score, based on the European Cooperative Oncology group (ECOG) performance status 694 score. This is a score ranging from 0 to 5, where 0 indicates no symptoms, 1 indicates 695 mild symptoms and above 1 indicates greater disability; LCNEC NSCLC type, large cell neuroendocrine carcinoma non-small cell lung cancer type; NOS, not otherwise specified; 696 KRAS, Kirsten Rat Sarcoma viral oncogene; PD-L1, programmed death ligand 1; TPS, 697 698 tumor proportion score; CR, complete response; PR, partial response; SD, stable 699 disease; *PD*, progressive disease; *DC*, disease control.

		Training cohort	Validation cohort
	p-value	n=55	n=80
Sex	1.00		
Male, no.(%)		30 (55%)	44 (55%)
Female, no.(%)		25 (45%)	36 (45%)
Age (years), mean (SD)	0.20	62 (10.1)	65 (7.5)
Smoking (never/ex/current)	0.64	5/44/6	12/51/17
Pack years, median (IQR)	0.90	29 (20)	30 (28)
PS, no. (%)	0.46		
0		16 (29%)	16 (20%)
1		29 (53%)	50 (62%)
≥2		10 (18%)	14 (18%)
Pathology, no.(%)	0.19		
Adeno		35 (64%)	50 (62%)
Squamous		10 (18%)	20 (25%)
LCNEC, NSCLC-type		0 (0%)	3 (4%)
NSCLC, NOS		10 (18%)	7 (9%)
		•	·
Mutations, no. (%)	0.86		

KRAS positive		19 (35%)	30 (38%)
	·		
PD-L1 TPS, no. (%)			
Negative <1%	1.00	30 (55%)	43 (54%)
Positive ≥1%		25 (45%)	36 (45%)
Negative <50%	0.66	43 (78%)	65 (81%)
Positive >50%		12 (22%)	14 (18%)
Unknown		0 (0%)	1 (1%)
			·
Brain metastases, no. (%)	0.67	13 (24%)	16 (20%)
Line of treatment, no (%)	0.63		
1		0 (0%)	1 (1%)
2		42 (76%)	56 (70%)
>2		13 (24%)	23 (29%)
	•		•
Best Overall Response	0.62		
CR/PR		11 (20%)	15 (19%)
SD		5 (9%)	16 (20%)
SD (PFS <6 months)		0 (0%)	6 (7%)
SD (PFS ≥6 months)		5 (9%)	10 (13%)
PD		39 (71%)	49 (61%)
	•		
DC			
at 6 months	0.85	16 (29%)	25 (31%)
at 12 months	0.83	12 (22%)	16 (20%)

Table 3. Predictive accuracy of selected individual and composite biomarkers, summary of training and

710 validation results

					Training					Validation						
Clinical outcome	Bio- marker	Predictor	Cut- off	Samples (n)	AUC (95% CI)	Sensitivity	Specificity	NPV	PPV		Samples (n)	AUC (95%-CI)	Sensitivity	Specificity	NPV	PPV
	PD-1 [⊤] TILs		90	42	0.82 (0.69- 0.95)	92%	67%	95%	52%		61	0.72 (0.57- 0.87)	72%	74%	86%	54%
DC 6	TIS		6.65	28	0.81 (0.65- 0.98)	100%	55%	100%	47%		40	0.57 (0.36- 0.77)	83%	39%	84%	37%
months	CD8+ IT-CD-8	probability for DC = 1 / (1 - exp (-3.5749 + 0.0031 * CD8 + 0.043 * IT-CD8)	0.167	55	0.83 (0.73- 0.94)	94%	62%	96%	50%		77	0.62 (0.50- 0.75)	64%	56%	76%	41%
	CD3+ IT-CD-8	probability for DC = 1 / (1 - exp (-2.3821 + 0.0806 * CD3 + 0.0175 * IT-CD8 + 0.0069 * CD3 * IT-CD8)	0.161	53	0.78 (0.65- 0.91)	94%	54%	95%	47%		74	0.68 (0.55- 0.80)	83%	46%	85%	43%
	PD-1 [⊤] TILs		90	42	0.82 (0.70- 0.94)	100%	64%	100%	43%		61	0.80 (0.65- 0.94)	86%	74%	95%	50%
DC 12	TIS		6.65	28	0.77 (0.58- 0.96)	100%	50%	100%	35%		40	0.63 (0.43- 0.82)	100%	39%	100%	26%
months	CD8+ IT-CD-8	probability for DC = 1 / (1 - exp (-4.0644 + 0.003 * CD8 + 0.0436 * IT-CD8)	0.122	55	0.85 (0.73- 0.96)	92%	63%	96%	41%		77	0.67 (0.53- 0.81)	68%	57%	88%	30%
	CD8+ TIS	probability for DC = 1 / (1 - exp (-5.7952 + 0.0224 * CD8 + 0.2346 * TIS + - 0.0021 * CD8 * TIS)	0.124	28	0.91 (0.79- 1.00)	100%	68%	100%	46%		38	0.59 (0.36- 0.82)	29%	68%	81%	17%

711

712

Figure 1



Figure 1

Figure 2



medRxiv preprint doi: https://doi.org/10.1101/2023.10.19.23297261; this version posted October 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.









Figure 2

Figure 3

С



medRxiv preprint doi: https://doi.org/10.1101/2023.10.19.23297261; this version posted October 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.





60

80

100

T: CD8+TIS (AUC 0.91) V: CD8+TIS (AUC 0.59)



F



Figure 3